Metastatic breast cancer treated with lapatinib with a prolonged benefit: A case report and a review of therapeutic options available

Tumori

Volumn 99, Issue 6, 2013, Pages

  Bianchi, Giulia Valeria ^a   Duca, Matteo ^a   Sica, Lorenzo ^a   Mariani, Gabriella ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Lapatinib; Metastatic breast cancer

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FULVESTRANT; GONADORELIN DERIVATIVE; LAPATINIB; LETROZOLE; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ADD ON THERAPY; ADULT; ARTICLE; ASTHENIA; AXILLARY LYMPH NODE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CASE REPORT; DRUG TOLERABILITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HAND FOOT SYNDROME; HER2 POSITIVE BREAST CANCER; HORMONAL THERAPY; HUMAN; LIVER INJURY; LYMPH NODE BIOPSY; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PROGESTERONE RECEPTOR NEGATIVE BREAST CANCER; QUALITY OF LIFE; SOCIAL BEHAVIOR; WORK CAPACITY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NITRILES; PACLITAXEL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUALITY OF LIFE; QUINAZOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TRIAZOLES;

EID: 84894229267     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161309900617     Document Type: Article

References (22)

1. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P: Survival of metastatic breast carcinoma patients over a 20-year period: A retrospective analysis based on individual patient data from six consecutive studies. Cancer, 104: 1742-1750, 2005. (Pubitemid 41437440)
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344: 783-792, 2001. (Pubitemid 32222155)
3. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med, 366: 109-119, 2012.
4. Fountzilas G, Razis E, Tsavdaridis D, Karina M, Labropoulos S, Christodoulou C, Mavroudis D, Gogas H, Georgoulias V, Skarlos D: Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer, 4: 120-125, 2003. (Pubitemid 36939418)
5. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ: Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol, 22: 1063-1070, 2004. (Pubitemid 41095039)
6. Gelmon KA, Mackey J, Verma S, Gertler SZ, Bangemann N, Klimo P, Schneeweiss A, Bremer K, Soulieres D, Tonkin K, Bell R, Heinrich B, Grenier D, Dias R: Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer, 5: 52-58, 2004. (Pubitemid 38821191)
7. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V: Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie, 28: 582-586, 2005. (Pubitemid 41513144)
8. Cancello G, Montagna E, D'Agostino D, Giuliano M, Giordano A, Di Lorenzo G, Plaitano M, De Placido S, De Laurentiis M: Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res, 10: R60, 2008.
9. Extra J-M, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, Guastalla JP, Spielmann M, Mauriac L, Misset JL, Serin D, Campone M, Hebert C, Remblier C, Bergougnoux L, Campana F, Namer M: Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist, 15: 779-809, 2010.
10. Montemurro F, Donadio M, Clavarezza M, Redana S, Jacomuzzi ME, Valabrega G, Danese S, Vietti-Ramus G, Durando A, Venturini M, Aglietta M: Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist, 11: 318-324, 2006.
11. Jones SE: Metastatic breast cancer: the treatment challenge. Clin Breast Cancer, 8: 224-233, 2008.
12. Von Minckwitz G, Du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 Study. J Clin Oncol, 27: 1999-2006, 2009.
13. Von Minckwitz G, Schwedler K Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S; GBG 26/BIG 03-05 study group and participating investigators: Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer, 47: 2273-2281, 2011.
14. Blackwell KL, Burstein KJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J: Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol, 28: 1124-1130, 2010.
15. Blackwell KL, Burstein KJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J: Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol, 30: 2585-2592, 2012.
16. Carlson RW, Theriault R, Schurman CM, Rivera E, Chung CT, Phan SC, Arun B, Dice K, Chiv VY, Green M, Valero V: Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol, 28: 3917-3921, 2010.
17. Cheung KL, Agrawal A, Folkerd E, Dowsett M, Robertson JF, Winterbottom L: Suppression of ovarian function in combination with an aromatase inhibitor as treatment of advanced breast cancer in premenopausal women. Eur J Cancer, 46: 2936-2942, 2010.
18. Park IH, Ro J, Lee KS, Kim EA, Kwon Y, Nam BH, Jung SY, Lee S, Kim SW, Kang HS: Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. J Clin Oncol, 28: 2705-2711, 2010.
19. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med, 355: 2733-2743, 2006. (Pubitemid 46021510)
20. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon y Cajal S, Arribas J, Baselga J: Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene, 28, 803-814, 2009.
21. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Canc Res Treat, 112: 533-543, 2008.
22. Bachelot T, Romieu G, Diéras V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Gonçalves A, Leheurteur M, Domont J, Gutierrez M, Curé H, Ferrero JM, Labbe-Devilliers C: Lapatinib plus capecitabine in patients with previously untreated brain metastases form HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase II study. Lancet Oncol, 14: 64-71, 2013.